Equillium (EQ) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rafael (RFL) has outperformed Equillium (EQ) over the past year, gaining 20.3% versus a loss of 2.1%. Over five years, EQ leads with a -76.1% price change compared with -94.7% for RFL. Equillium is the larger company by market cap ($89.4 million vs $83.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | RFL |
|---|---|---|
| Share price | $1.41 | $1.60 |
| Market cap | $89.41M | $83.20M |
| 1-day change | -2.08% | +8.11% |
| YTD return | -9.03% | +35.59% |
| 1-year return | -2.08% | +20.30% |
| 5-year return | -76.14% | -94.69% |
| EPS (TTM) | $-0.14 | $-0.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $3.96 |
| 52-week low | $0.76 | $1.12 |
| Distance from 52-week high | -60.17% | -59.60% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +507.09% | — |
| Average volume | 583.72K | 160.39K |
| Shares outstanding | 63.41M | 51.21M |
| Employees | 14 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RFL has outperformed EQ by 22.4 percentage points over the past year.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
EQ vs RFL FAQ
Which is bigger, Equillium or Rafael?
Equillium (EQ) is larger, with a market capitalization of $89.41M compared with $83.20M for Rafael (RFL).
Which stock has performed better over the past year, EQ or RFL?
RFL returned +20.30% over the past 12 months, compared with -2.08% for EQ (price return, excluding dividends). Past performance does not predict future results.
Are Equillium and Rafael in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.